Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TFG-002
- Development stage
- Preclinical
- Lead developer
- TreeFrog Therapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
01
Overview
TFG-002 is an induced pluripotent stem cell (iPSC)-derived 3D hepatic microtissue cell therapy under preclinical development by TreeFrog Therapeutics for the treatment of liver diseases, including acute liver failure. The therapy is manufactured using TreeFrog's proprietary C-Stem™ platform, which is a closed, bioreactor-based capsule technology designed for scalable cell expansion and differentiation under GMP-compliant conditions. By delivering pre-organized 3D hepatic microtissues rather than single-cell suspensions, TFG-002 aims to improve cell survival, integration, and functional restoration in the damaged liver.
Beyond the preview
Go deeper on TFG-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TFG-002.